1. Home
  2. GAIA vs SCYX Comparison

GAIA vs SCYX Comparison

Compare GAIA & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gaia Inc.

GAIA

Gaia Inc.

N/A

Current Price

$1.26

Market Cap

32.9M

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$3.56

Market Cap

37.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GAIA
SCYX
Founded
1988
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.9M
37.9M
IPO Year
1999
2014

Fundamental Metrics

Financial Performance
Metric
GAIA
SCYX
Price
$1.26
$3.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$3.38
★ $32.67
AVG Volume (30 Days)
★ 95.5K
66.5K
Earning Date
11-02-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
18.18
★ 61.36
EPS
★ N/A
N/A
Revenue
★ $4,500,000.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$977.86
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 12.50
N/A
52 Week Low
$1.16
$0.66
52 Week High
$4.48
$6.09

Technical Indicators

Market Signals
Indicator
GAIA
SCYX
Relative Strength Index (RSI) 40.37 37.85
Support Level $1.18 $0.66
Resistance Level $1.47 $4.15
Average True Range (ATR) 0.07 0.21
MACD -0.01 -0.00
Stochastic Oscillator 8.33 31.57

Price Performance

Historical Comparison
GAIA
SCYX

About GAIA Gaia Inc.

Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. The company operates in a single reporting segment. Its revenues is derived from subscription fees for services related to streaming content to the members. Geographically, it derives a majority of its revenue from the United States and also has an International presence.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: